Evidence map›Paper›PMID 38851856›Full record

ArticleCommunications biology2024

Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro.

Simone S Schüller, Soumik Barman, Raul Mendez-Giraldez, Dheeraj Soni, John Daley, Lindsey R Baden, Ofer Levy, David J Dowling

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. The recent advances in vaccine adjuvants.Frontiers in immunology · 2025
    Review
  5. Review
  6. Article
  7. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simone S Schüller *Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
Soumik Barman *Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-3641-2125
Raul Mendez-GiraldezBeckman Coulter Life Sciences, Brea, CA, USA.ORCID 0000-0003-1853-9429
Dheeraj SoniPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-5555-2051
John DaleyDana Farber CyTOF Core Facility, Dana-Farber Cancer Institute, Boston, MA, USA.
Lindsey R BadenHarvard Medical School, Boston, MA, USA.
Ofer LevyPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA. ofer.levy@childrens.harvard.edu.ORCID 0000-0002-5859-1945
David J DowlingPrecision Vaccines Program, Boston Children's Hospital, Boston, MA, USA. david.dowling@childrens.harvard.edu.ORCID 0000-0003-1095-6156

Funding

Infant HIV Vaccination: B-cell Lineage Study272201800047C · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2018 to 2022
$13.6M
Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
X-RAY CRYSTALLOGRAPHY OF HIV PROTEASEU01AI027220 · NIAID · ABBOTT LABORATORIES · PI PLATTNER, JACOB J · 1988 to 1992
–
NIAID NIH HHS 75N93019C00044U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 272201800047CU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 272201800047C-P00003-9999)
6 · The paper itself

Abstract

Vaccination reduces morbidity and mortality due to infections, but efficacy may be limited due to distinct immunogenicity at the extremes of age. This raises the possibility of employing adjuvants to enhance immunogenicity and protection. Early IFNγ production is a hallmark of effective vaccine immunogenicity in adults serving as a biomarker that may predict effective adjuvanticity. We utilized mass cytometry (CyTOF) to dissect the source of adjuvant-induced cytokine production in human blood mononuclear cells (BMCs) from newborns (~39-week-gestation), adults (~18-63 years old) and elders (>65 years of age) after stimulation with pattern recognition receptors agonist (PRRa) adjuvants. Dimensionality reduction analysis of CyTOF data mapped the BMC compartment, elucidated age-specific immune responses and profiled PRR-mediated activation of monocytes and DCs upon adjuvant stimulation. Furthermore, we demonstrated PRRa adjuvants mediated innate IFNγ induction and mapped NK cells as the key source of TLR7/8 agonist (TLR7/8a) specific innate IFNγ responses. Hierarchical clustering analysis revealed age and TLR7/8a-specific accumulation of innate IFNγ producing γδ T cells. Our study demonstrates the application of mass cytometry and cutting-edge computational approaches to characterize immune responses across immunologically distinct age groups and may inform identification of the bespoke adjuvantation systems tailored to enhance immunity in distinct vulnerable populations.

Indexed as

Adjuvants, ImmunologicLeukocytes, MononuclearAdolescentAdultAgedAge FactorsFemaleHumansImmunity, InnateInfant, NewbornInterferon-gammaMaleMiddle AgedYoung AdultAdjuvants, ImmunologicInterferon-gamma

Identifiers

PMID38851856
PMCPMC11162429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.